Biomarker Study of Elotuzumab in High Risk Smoldering Myeloma
Completed · Phase 2
Conditions studied: Smoldering Multiple Myeloma
In brief
The purpose of this study is to determine whether elotuzumab will improve response in patients with high risk smoldering myeloma who have more CD56\^dim cells (a marker for the health of the body's immune system)
Key facts
- Study ID
- NCT01441973
- Run by
- Bristol-Myers Squibb
- People needed
- 41
- Starts
- 2011-12-28
- Expected to finish
- 2017-01-17
- Last updated by the study team
- 2018-01-23
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Sharp Clinical Oncology Research — San Diego, California, United States
- Yale University School Of Medicine — New Haven, Connecticut, United States
- Va Connecticut Healthcare System — West Haven, Connecticut, United States
- Winship Cancer Institute. — Atlanta, Georgia, United States
- University Of Chicago Medical Center — Chicago, Illinois, United States
- Investigative Clinical Research Of Indiana, Llc — Indianapolis, Indiana, United States
- Dana Farber Cancer Institute — Boston, Massachusetts, United States
- Dana-Farber Cancer Institute — Boston, Massachusetts, United States
- Washington University School Of Medicine — St Louis, Missouri, United States
- Weill Cornell Medical College — New York, New York, United States
- Mount Sinai Medical Center — New York, New York, United States
- Mid Dakota Clinic, Pc — Bismarck, North Dakota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.